Spero therapeutics to present at upcoming investor conferences

Cambridge, mass., may 11, 2022 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (mdr) bacterial infections and rare diseases, today announced that ankit mahadevia, m.d., president and chief executive officer of spero therapeutics, will present and be available for one-on-one meetings at the 2022 rbc capital markets global healthcare conference and the h.c. wainwright global investment conference, which are taking place may 17-18 and may 23-25, respectively. details for the presentations are as follows:
SPRO Ratings Summary
SPRO Quant Ranking